Abstract. Medical science is currently perceived as underperforming. This is because of the relatively slow recent rate of development of new disease treatments. This has been blamed on cultural, regulatory, and economic factors that generate a so-called "Valley of Death", hindering new drug candidates from being moved into clinical trials and eventually approved for use. We propose, however, that for neurodegenerative diseases, a relative decline of human brain tissue research is also a contributor. The present pharmacological agents for treating Alzheimer's disease (AD) were identified through direct examination of postmortem human brain tissue more than 30 years ago. Since that time the percentage of research grants awarded to human brain tissue-using projects has dropped precipitously and publication rates have stagnated. As human brain tissue research has played a central and often initiating role in identifying most of the targets that have gone to AD clinical trials, it is proposed that the rate of discovery of new targets has been curtailed. Additionally, the continued rejection of cortical biopsy as a diagnostic method for AD has most probably depressed the perceived effect sizes of new medications and contributed to the high Phase II clinical trial failure rates. Despite the relative lack of funding, human brain discovery research has continued to make important contributions to our understanding of neurodegenerative disease, and brain banks have played an essential role. It is likely that the pace of discovery will dramatically accelerate over the coming decades as increasingly powerful tools including genomics, epigenetics, transcriptomics, regulatory RNA, gene expression profiling, proteomics, and metabolomics are applied. To optimize the promise of these new technologies, however, it is critical that brain banks are rejuvenated by enhanced governmental and/or private support.
disheartening and provocative. A nagging uneasiness with tangible progress, common across all biomedical research fields, has broken out into the open, forcing our collective gaze into what has been termed the "Valley of Death" [1] . Despite the stunning avalanche of data emanating from powerful new technology, the production rate of new effective medications has been steadily dropping. Neurodegenerative research is no exception. The major Food and Drug Association (FDA)-approved therapeutic agents for AD are based on work done three to four decades ago. As a result, our most urgent question has become, "Where have we gone wrong?" S220
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The "Valley of Death" has been variously portrayed as a chasm between biomedical researchers and patients, or between basic science researchers in academia and applied science researchers in the pharmaceutical industry, or between basic science ideas and the hurdles they must cross to regulatory approval. What is clear is that the translation of basic science discoveries to drugs with obvious real-world benefits is becoming less, rather than more frequent than any of us are comfortable with. Multiple reasons for the gap have been advanced, including a shift in National Institutes of Health research grants to PhDs rather than MDs, the increasingly complex barriers to FDA approval, the cost escalation of large clinical trials, the increasing dependence on for-profit corporate involvement, and the realization that many diseases are etiologically heterogeneous [2] [3] [4] .
Another possible cause has received much less attention but may be much more important. In 2002, the National Dialogue on Cancer, convened to understand why the "war on cancer" was falling short of expectations, concluded that of the ten most important roadblocks to finding cures for cancer, the single most critical one was inadequate availability of "high-quality, highly characterized human tissues for translational research" (Carolyn Compton, Former Director, NCI Office of Biorepositories and Biospecimen Research). As a result, in 2003 the NCI published the National Biospecimen Network Blueprint and in 2005 formed the Office of Biorepositories and Biospecimen Research (OBBR) to stimulate and coordinate the development of tissue resources and capabilities. The need for better access to high quality tissue has been widely cited by other groups, including the NIH Blueprint for Neuroscience Research [5] , the Genomics and Personalized Medicine Act of 2007, the Department of Health and Human Services' "Personalized Health Care Report" (2007) , and the President's Council of Advisors on Science and Technology: Priorities for Personalized Medicine (2008) .
This article presents the viewpoint that the stalemate in AD translational research may be at least partially attributable to a relative decline in human brain tissue-based research, not only due to poor availability of suitable tissue but also to funding declines and reduced publications emanating from human tissuebased research. Current FDA-approved therapies for AD are still largely restricted to cholinergic replacement, an approach that was suggested by human brain tissue studies in the 1970 s [6] [7] [8] [9] . The only other approach, directed at blocking glutamatergic excitotoxicity (memantine/Namenda), was approved by the FDA in 2003 but the first description of excitotoxicity had been in 1957 [10] and its application to AD was first envisioned in the early 1980 s. Thirty years of ensuing research has really produced no new effective agents.
DECLINE IN FUNDING AND PUBLICATIONS USING HUMAN BRAIN TISSUE
We investigated whether or not there has been a decline in both the number of funded AD research projects and the number of AD publications that utilize human brain tissue. A search of the NIH RePORTER website database (http://projectreporter.nih.gov/reporter.cfm) was performed using "Alzheimer's" as a key word within the text of project titles, abstracts, and terms. The total number of awards was recorded and all awards with an abstract were examined to determine the proportion that used human brain tissue. For years with more than 100 projects with abstracts, only the first 100 abstracts were examined to determine the proportion. Searches were done every two years over a time period extending from 1994 through 2010 and results are shown in Fig. 1 . Over this time period, the proportion of awards that used human brain tissue peaked at 47% in 1996 and then steadily declined to only 5% in 2010 (Fig. 1a) . As the total number of AD awards also declined (Fig. 1b) , over time the absolute number of awards that have used human brain tissue has been considerably reduced. The US National Library of Medicine was then searched for AD publications using their PubMed website (http://www.ncbi.nlm.nih.gov/pubmed). The percentage of publications that used human brain tissue was estimated by reading abstracts from the first 100 articles listed for each year. The only search term used other than year was "Alzheimer's". Only articles with an abstract were included and review articles were excluded. As for funding awards, searches were done over a time period extending from 1994 through 2010. The results, shown in Fig. 2 , indicate that the percentage of AD publications that used human brain tissue in 2010 had dropped to one-quarter of what it was in 1994 (Fig. 2a) while in the same time period the total number of AD publications more than tripled (Fig. 2b) . The estimated absolute number of AD publications using human brain tissue remained static, with 492 in 1994 and 443 in 2010.
WHAT IS THE EVIDENCE THAT HUMAN BRAIN TISSUE-BASED RESEARCH IS IMPORTANT?
Although it appears that human brain tissue-based AD research funding and publications have declined, how do we know that this has had any impact on AD translational research? We have pointed out that the major FDA-approved agents for the defining symptoms of AD (cognitive loss) act to replace the cortical cholinergic deficit that was discovered through direct examination of AD and control brains [7] [8] [9] . The only non-cholinergic FDA-approved agent, memantine, can be considered to have had contributing origins from animal, cell culture, and human studies. The animal studies, dating from 1951 [11, 12] , demonstrated the neurotoxicity of glutamate and molecular analogues. The term "excitotoxicity" was coined by Olney in 1974 [10] . The idea of using excitotoxic animal models to model AD appears to have first been mentioned in the early 1980 s [13] . The first PubMed linkage of AD to glutamate and NMDA receptors was in 1986 when Geddes and Cotman described the localization of NMDA receptors to AD-susceptible hippocampal sectors [14, 15] . A 1985 cell culture study, meanwhile, had used glutamate to induce paired helical filaments [16] .
What, however, has been the contribution of human brain tissue studies to approaches developed in subsequent years? We searched the NIH website (http://www.clinicaltrials.gov), for agents registered for AD clinical trials ( Table 1 ). The therapeutic approaches have been loosely grouped into anti-amyloid, anti-tau, neurotransmitter modulation, anti-aging, vascular, and anti-inflammatory. Agents without a clear molecular mechanism are not listed. For each approach we searched the literature to determine whether the origin could be attributed to studies of human brain tissue, cell culture models, animal models, human molecular genetics, or epidemiology.
The most obvious approach to AD therapy has been to prevent or remove plaques and tangles. These were first linked to the clinical entity of AD by Alzheimer in 1906 [17] but a molecular strategy was not possible until Glenner and Wong isolated amyloid-␤ peptide Table 1 Agents listed by the NIH website, http://www.clinicaltrials.gov, as registered for AD clinical trials. Agents are grouped into approaches by molecular mechanism. A literature search was done for each approach to determine whether the origin could be attributed to studies of human brain tissue (HBT), cell culture models (CLCT), animal models (ANML), human molecular genetics (HMG) or epidemiology (EPID). Dates of first conception and important original articles or reviews are listed [18] and further critical steps toward solidifying the "amyloid hypothesis" included working out the entire amino acid sequence, localizing the gene to chromosome 21, developing antibodies, identifying causal mutations in early-onset AD families, discovering the enzymes responsible for cleavage, and creating transgenic mice bearing the causative mutations [19, 20] . The amyloid hypothesis clearly originated from human brain tissue studies but its subsequent elaboration vividly illustrates how a constant interchange between human brain tissue studies and those involving cell and animal culture models as well as molecular genetics leads to the rapid development of a seed idea.
The molecular dissection of tangles occurred almost concurrently with that of amyloid as tau presence and hyperphosphorylation within tangles was first described from human brain tissue studies by Grundkelqbal in 1986 [21] . As with the amyloid hypothesis, a synergistic attack using multiple methods quickly established a critical mass of evidence and raised the idea that the toxicity of abnormal protein aggregates might be a common cause of neurodegeneration [22, 23] .
Neurotransmitter replacement was the first truly molecular-based approach to neurodegenerative disease, beginning with the discovery of the striatal dopaminergic deficit in Parkinson's disease brains by Birkmayer and Hornykiewicz in 1961 [6, 24] and then the cortical cholinergic deficit in AD by three groups in the United Kingdom in 1976 [6] [7] [8] [9] . Subsequently, several other neurotransmitters have been scrutinized for a possible role.
While memantine was developed to block NMDA receptor-mediated glutamate toxicity, another glutamatergic approach has been to positively modulate AMPA receptors. This has been based on a combination of methods, including cell culture and hippocampal slice model work done in 1990 that showed long-term potentiation is induced by AMPA receptor agonists [25] , followed by human brain tissue research in 1993 and 1994 showing decreased AMPA receptor subunit density in AD entorhinal area and neocortex [26, 27] .
The prospects for GABA receptor modulation were originally not compelling as studies of human and control AD brain in the 1980 s showed only modest loss of GABAergic components [28] . However, in 1997 studies in hippocampal slices indicated that GABA A receptor inverse agonists enhance long term potentiation [29] and in 2003 were shown to increase performance of treated mice on the Morris water maze [30] .
Tacrine was shown to increase action potential duration of in vitro central histaminergic neurons in 1988 [31] and the HT 3 autoreceptor was shown to regulate the release of not only histamine but also acetylcholine (ACh), norepinephrine, and dopamine from presynaptic nerve endings. Initial reports in 1989 on histamine in AD and control brain were contradictory but later reports agreed on significant cortical depletion [32] . In 1996, in vivo microdialysis experiments in rat brain demonstrated HT 3 antagonist-mediated release of ACh in rat cerebral cortex [33] while rats receiving intracerebroventricular HT 3 antagonist had improved short-term memory [34] .
A number of different approaches have first originated in their identification with the aging process and therefore credit for their application to AD therapy is not really possible to assign as it was natural and obvious from the extant aging literature to investigate these as possible causes of AD. These include sex hormone modulation, antioxidants, and RAGE inhibitors. The latter two of these approaches, however, received important support from human brain tissue studies [35, 36] .
The linkage of AD to atherosclerosis, arteriosclerosis, and arteriolosclerosis was already being debated, based on human brain studies showing their coincidence, by Alzheimer and his contemporaries [17, 37] , and the debate continues but has nonetheless resulted in several agents being given clinical trials. A series of negative clinicopathological studies in the middle of the twentieth century stifled this approach but the discovery in the early 1990 s of the association of the apolipoprotein E ε4 genotype with AD, followed by epidemiological identification of vascular AD risk factors, brought it sharply back into prominence. Human brain tissue studies can be awarded precedence in developing the apolipoprotein E ε4 connection with AD, with two publications in 1991. Diedrich and colleagues used differential screening of cDNA libraries from diseased and normal brains to show increased ApoE expression in AD and scrapie while in Japan, Namba and colleagues showed that ApoE is bound to amyloid plaques in both AD and kuru brains. Subsequently, Sparks and colleagues showed increased coronary artery stenosis in middle-aged subjects with brain amyloid plaques [38] and Roses and colleagues reported increased prevalence of the ε4 allele in familial and sporadic AD [39, 40] . This was followed up by multiple epidemiological studies reporting that many of the risk factors for cardiovascular disease were also risk factors for AD [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . Several approaches to AD therapy, including the use of cholesterol-lowering drugs, anti-hypertensive agents, platelet aggregation inhibitors, anti-diabetic agents, arteriolar vasodilators, and glucose/metabolic agents can be logically traced to this resurgence of the vascular hypothesis.
The only other major approach not yet discussed is the inflammatory hypothesis. Although phagocytic glial cells had been known since Alzheimer's time to be situated near senile plaque amyloid cores, the virulence of the microglial reaction to amyloid plaques, as demonstrated with new immunohistochemical methods by McGeer and colleagues in 1987 [51] was a startling revelation. Subsequently, localization of many components of the immune response to AD brain tissue solidified the findings [52, 53] and led quickly to the first clinical trial of an anti-inflammatory agent [54] while epidemiological and molecular genetic associations have continued to come in [55, 56] .
This brief review of the origins of experimental therapeutic approaches to AD undoubtedly has not given adequate credit to all the contributors but it is evident that human brain tissue-based research has played a central and often initiating role. It is hard to avoid the conclusion that the stagnation of such work over the last 20 years has imposed limitations on the generation of new ideas and new targets.
DETRIMENTAL EFFECTS OF THE DECISION NOT TO USE BRAIN TISSUE-BASED DIAGNOSIS FOR AD
It has been more than four decades since a consensus developed not to use cortical biopsy to diagnose AD [57] . This may be one of the most significant factors responsible for the failure to develop new therapeutics. Clinical trials must utilize sufficient numbers of subjects so that the possibility of a false negative or false positive result is minimized. Estimating the appropriate minimal subject number requires an initial assessment of the effect size of the medication and this is usually done with pilot studies (e.g., Phase II trials) where a relatively small number of subjects clinically diagnosed with AD receive the agent to be tested. For AD, the effect of the treatment on a measure of cognition, usually the Alzheimer's Disease Assessment Scale-cognitive subscale is used. Recently, biomarker and imaging measures have been proposed as surrogate measures. Regardless of the specific measure of treatment effect, analysis of the pilot data for treated and placebo groups gives an estimate of the medication's effect size, most simply represented by the percentage of subjects that had a statistically or clinically significant response. The effect size then is used to calculate the minimal trial subject number needed to minimize both false positive and false negative results. A major problem for AD clinical trials has been that effect sizes are often low and therefore very large numbers of subjects are needed, making the trials very expensive and risky. Consequently, many Phase II trials do not proceed to definitive Phase III trials because of small effect size; small effect size is the most common reason for Phase II trial failures across medical fields [58] .
Effect size in AD trials is very probably lower than it might be due to inclusion of subjects whose dementia is not due to AD. According to a recent study of data from all National Institute on Aging AD Centers [59] , the sensitivity of the clinical diagnosis of AD, as compared to new consensus autopsy criteria [60] , may be about 80%. If a similar level of accuracy exists for subject selection for AD clinical trials, then 20% of subjects entered into trials may not have AD but another dementing disorder. If the agent being tested in the pilot study is effective only in patients with AD, then there will be a 20% reduction in effect size, compared to what it would be if all the pilot study subjects really had AD. The consequences of this for the calculation of subject number for the definitive trial depend on the overall effect size achieved by the test agent in the pilot trial. For effect sizes over 50%, a 20% diagnostic error does not change the required subject number much, but if the effect size is lower than 50%, the 20% diagnostic error may double or even triple the required subject number, greatly increasing the cost of the trial. The significance of this may be appreciated by knowing that acetylcholinesterase inhibitors, which are the most commonly-used AD therapeutic agents, all have effect sizes that are much less than 50% [61] [62] [63] .
Using cortical biopsy to more accurately select subjects for clinical trials could, for agents with selective benefit for AD, increase the effect size, reduce the number of subjects needed for a definitive clinical trial and therefore increase the number of agents chosen to go on to Phase III trials. Why then, have cortical biopsies not been used? The rationale has been that the risks outweigh the benefits as disease-modifying treatments for AD have not been available and most elderly subjects with idiopathic dementia will be treated for presumptive AD anyway [57] . The usage of cortical biopsy for clinical trial selection, however, provides a benefit that has not previously been considered, while serious complications are rare and could potentially be reduced by using needle biopsy rather than open brain biopsy [64, 65] . When faced, decades ago, with a similar predicament at a time when glioblastoma and other brain tumors had no effective treatment, neurosurgeons and oncologists readily accepted that a biopsy diagnosis was essential to guide clinical trials.
Furthermore, oncologists have become aware of disease heterogeneity that further reduces the effect size of medications. This heterogeneity, originating in molecular diversity within a given histologicallydefined tumor type, means that not everyone with the same initial biopsy diagnosis responds the same way to a given agent, and, due to tumor cell genetic evolution, even the same patient's response may vary over time. Molecular and genetic diversity within what used to be thought of as homogeneous diseases has given rise to the concept of "personalized medicine" and the need to know not only the histological diagnosis but also the molecular tissue changes that might cause one patient to be drug-sensitive and another drug-resistant [66] . Identifying these changes requires diseased tissue. While AD and cancer are very different diseases, there has been an increasing realization, from many human brain tissue-based studies, that AD is also pathologically heterogeneous. Aside from having different stages dependent on topographical spread of the signature plaques and tangles or the severity of amyloid angiopathy [67, 68] , there are also several subtypes including AD with Lewy bodies, itself subdivided into neocortical and amgydala-predominant forms [69, 70] , AD with vascular lesions, with different lesion types including large infarcts, lacunar infarcts, microscopic infarcts, and leukoencephalopathy [71] [72] [73] [74] , AD with TDP-43 positive protein aggregates [75] , AD with hippocampal sclerosis [76] [77] [78] , and AD with argyrophilic grains [79] [80] [81] [82] . Additionally, AD may co-exist with progressive supranuclear palsy and other neurodegenerative conditions. If patients at different amyloid or tangle stages of AD or with different AD subtypes differ in their responses to a test medication, then the effect size in clinical trials would be further reduced. It would be extremely useful to be able to subtype AD trial patients with cortical biopsy as a trial that initially was thought to be completely negative might be found, on closer examination, to have had a significant benefit for an identifiable patient subset. A recent study has demonstrated the capability of cortical biopsy to identify AD with cortical Lewy bodies and AD with TDP-43 positive pathology [83] and cortical biopsy with assessment for amyloid-␤ and phosphorylated tau has been shown to predict the probability of later progression to dementia [84] . A cortical biopsy could also demonstrate the density and morphological types of plaques and whether tangles have spread into the cortex or are still confined to limbic areas, features which are likely to affect treatment response. Recent biomarker approaches to diagnosing AD more accurately [85] [86] [87] are a considerable improvement over previous clinical methods confined to functional and neuropsychological assessment, but will undoubtedly still lack sensitivity and specificity compared to biopsy and will be largely unable to detect AD pathological heterogeneity. Correlation of these biomarker methods with human brain tissue, autopsy [88] [89] [90] [91] , and biopsy findings [92] have already been used to a limited degree but more of these studies are critically needed.
WHAT CAN BE DONE TO STIMULATE HUMAN BRAIN TISSUE-BASED RESEARCH?
What is the cause of the marked reduction in AD research using human brain tissue? We postulated two reasons: 1) declining availability of suitable human brain tissue, and 2) declining success rate, relative to all proposals, of research proposals that use human brain tissue. We did not have access to data on the second of these factors so we examined the first.
We attempted to determine whether the number of functional brain banks and available human brain tissue has declined over the past 20 years. A PubMed search revealed two papers published in 1991 and 1994 that give a baseline for what was available at that time [93] [94] [95] . At the time of the survey published in 1995, 69 brain banks were listed for the US, Europe, and Canada, collectively holding more than 45,000 brains. A detailed breakdown of diagnoses was not given but 69 banks held AD brains and 57 held control brains. Thirty-nine banks kept frozen tissue (fixed tissue is generally universally available) while 10 did not and 18 did not have that information available. Unfortunately there were no such comprehensive surveys listed by PubMed after this last 1995 article. We therefore used an open internet search for brain banks to compile a contemporary listing of brain banks with AD and control tissue. BrainNet Europe is a consortium of 19 separate brain banks (http://www.brainnet-europe.org/). Their website lists many brain banks from around the world, of which 83 or more appear to have AD and control brain tissue. The International Brain Banking Network (IBBN) website (http://www.intbbn.org/registry-ofbrain-banks.aspx) lists 87 brain banks that appear to have AD and control brain tissue; these are composed mainly of 51 US and 24 European brain banks. A listing of the number of brains banked is not given but as many of these banks are the same as those listed in the 1995 survey, it is reasonable to conclude that many thousands of AD and control brains must be available for research. Therefore it does not seem that there should be a lack of AD brain tissue, however, various sources suggest that there is a critical shortage of normal control brain tissue .
Although 45,000 brains would seem enough for an almost infinite amount of AD research, again the recent experience of the NCI with tissue procural is instructive. In 2005 the NCI announced a new initiative, the Cancer Genome Atlas, to catalogue all the genetic mutations associated with cancer. The pilot project would aim to do this for three types of cancer, glioblastoma, serous ovarian cancer, and squamous cell lung carcinoma. For all of these, the original plan was to sequence 1,500 samples, which were to be derived from dozens of tissue banks. Preliminary estimates from the tissue banks had indicated that each could provide at least 500 samples. Once collection was underway, however, the great majority of samples were found to be unsuitable, due to inadequate consent, not enough tissue, inadequate tissue quality, and other reasons. One bank had claimed to have more than 12,000 samples of glioblastoma but in the end only 18 of these were suitable. Eventually, barely 500 samples were obtained for the ovarian cancer, not even 500 for glioblastoma, and collection efforts for lung cancer were suspended due to the huge efforts involved with obtaining the samples (Carolyn Compton, Former Director, NCI Office of Biorepositories and Biospecimen Research). Until such a massive quality-control assessment is done on AD and control brain tissue, we will not really know how many of those held in tissue banks are suitable for modern molecular studies. A major difference between tissue banking for cancer and tissue banking for AD is that cancer tissue banking is almost entirely done from biopsies whereas AD tissue banking is almost entirely done from autopsies. While autopsy offers the ability to obtain large amounts of tissue, it also brings with it many confounding factors including the tendency for gradual changes in the final months of life due to chronic illness, more radical physiological alterations associated with the agonal period immediately preceding death, and deterioration associated with the postmortem interval (PMI). Although studies do not all agree, it appears that RNA integrity and measures of gene expression both decline with increasing PMI, although with substantial variability between individual transcripts [120] .
Susceptible transcripts include some that are of interest to neurodegenerative research, including synaptophysin [121] , hsp-70 [127] , ADAM9, LPL, PRKCG, SERPINA3 [129] , and alpha-synuclein [130] . Additionally, RNA integrity may be lost with repeated cycles of freezing and thawing [131, 132] , a problem common to all tissue banking. As a result of these issues, inadequate RNA integrity may substantially reduce the number of banked brains that are suitable for gene expression research. Some programs have reported that only one-third to one-half of cases have RNA suitable for molecular research methods [133] . Moreover, it is apparent that deterioration of molecular entities after death varies widely depending on what is being measured. Highly volatile energy storage molecules such as ATP disappear within minutes [134, 135] and catecholamines drop precipitously within the first few hours [136] . Some intensely-studied proteins are reported to show degradation within the first 4-8 hours of death, including ␣-synuclein and sarkosyl-insoluble tau [137] . The postmortem integrity of post-translational protein modifications is largely unknown, although it has been reported that tau protein is dephosphorylated within 30 minutes after death [138, 139] . The advent of "metabolomics", offering the comprehensive study of small molecules, may be severely hampered by long PMI and/or agonal tissue deterioration. Rapid autopsy programs, currently very few in number [138, 139] , may need to become much more commonplace.
Although we have no data on the success rate of NIH grant proposals that are primarily human tissuebased, anecdotal experience suggests that these are often rejected on grounds that they are "descriptive only", "are not hypothesis-driven", and any conclusions are "not testable". The need for a continual back-and-forth between human tissue and experimental models seems not to be appreciated as it was in the not-too-distant past. The evidence put forth here documents the major role that human tissue-based research has had in discovering new targets as well as in validating targets identified with other modalities. Perhaps there should be an NIH study section devoted to human tissue-based research and/or a specific subset of the NIH budget set aside for this.
THE FUTURE OF HUMAN BRAIN TISSUE-BASED AD RESEARCH
Despite the handicaps limiting human brain tissuebased research its future is bright, in part because of the legacy of its past. The linkage of ubiquitin to tangles and plaques [140, 141] , Lewy bodies [142, 143] , and frontotemporal lobar degeneration (FTLD) [144, 145] in the 1980 s and 1990 s was instrumental in leading to the more recent discovery of FTLD and/or motor neuron disease-associated mutations in progranulin [146, 147] , CHMP2B [148] , FUS [149] , TDP-43 [150, 151] , UBQLN2 [152] , and C9ORF72 [153, 154] genes. The discovery of the abnormal phosphorylation of tau [21] has been repeated with ␣-synuclein [155] and then TDP-43 [156] . The value of "deep phenotyping" through neuropathological study has been appreciated by molecular geneticists, who have found that an accurate diagnosis of AD can greatly reduce the number of subjects needed for whole genome association studies, and such studies have already contributed handfuls of new targets at a time [157, [157] [158] [159] [160] . Additionally, autopsy-referenced molecular genetic dissection of other neurodegenerative diseases have provided important comparisons [147, 161, 162] . Postgenomics studies, including those involving epigenetic factors, microRNA, transcriptomics, proteomics, and metabolomics, will all depend even more heavily on human brain tissue. It is essential that brain banks receive enhanced governmental or private support, or exploit user-pay systems more heavily. Once again, we may look to cancer research to lead the way, as the NCI has called for an increased understanding of tissue banking economics [163, 164] to help realize their potential.
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